Abstract
To investigate cardiovascular disease (CVD) risks caused by blood pressure (BP) of 130-139/80-89 mmHg among Chinese adults with different glucose metabolism. A prospective population-based cohort of 2,132 adults in Shanghai was established in 2002, and CVD information was collected during 10.9 years of follow-up. After assessing the association between BP categories and incident CVD, we analyzed the risk for CVD by blood glucose categories and BP categories combined by using multiple Cox regression analysis among 1,419 participants at follow-up. The corresponding incidence of CVD per 1,000 person-years for the BP <130/80 mmHg, 130-139/80-89 mmHg, and ≥140/90 mmHg or treated groups were 3.0, 6.0, and 13.9, respectively. After adjusting for age, sex, and other factors, BP ≥140/90 mmHg was significantly associated with a higher CVD risk in general (hazard ratio 2.68 [95% CI 1.36-5.25]) and in various blood glucose categories (normoglycemia 2.59, prediabetes 3.03, diabetes mellitus [DM] 4.98). However, BP of 130-139/80-89 mmHg was significantly associated with a higher CVD risk in an estimated baseline 10-year atherosclerotic CVD (ASCVD) risk ≥10% (3.82 [1.42-9.78]) or DM (3.54 [1.05-11.88]) but not in the general population or for...Continue Reading
References
Feb 1, 1993·Diabetes Care·J StamlerD Wentworth
Jun 23, 1998·Lancet·L HanssonS Westerling
Sep 11, 1998·BMJ : British Medical Journal
Aug 11, 2000·BMJ : British Medical Journal·A I AdlerR R Holman
Sep 23, 2006·European Journal of Endocrinology·Jing-Yan TianMin Luo
Jun 15, 2007·European Heart Journal·Giuseppe Mancia The task force for the management of arterial hypertension of the European Society of Cardiology
Aug 8, 2007·Journal of the Cardiometabolic Syndrome·Emma KabakovNaftali Stern
Sep 4, 2007·Lancet·Anushka PatelB Williams
Sep 12, 2008·The New England Journal of Medicine·Rury R HolmanDavid R Matthews
Mar 14, 2009·European Heart Journal·Xin DuUNKNOWN ADVANCE Collaborative Group
Jan 29, 2010·Diabetes Care·UNKNOWN American Diabetes Association
Mar 17, 2010·The New England Journal of Medicine·William C CushmanFaramarz Ismail-Beigi
Jun 3, 2011·Circulation·Sripal BangaloreFranz H Messerli
Dec 20, 2013·JAMA : the Journal of the American Medical Association·Paul A JamesEduardo Ortiz
Mar 7, 2014·Diabetes Care·Karen L MargolisDavid C Goff
Aug 19, 2014·Lancet·UNKNOWN Blood Pressure Lowering Treatment Trialists' Collaboration
Jan 28, 2015·Hypertension·Miaoyan QiuJingyan Tian
Nov 10, 2015·The New England Journal of Medicine·UNKNOWN SPRINT Research GroupWalter T Ambrosius
Jan 3, 2016·Lancet·Dena EttehadKazem Rahimi
May 31, 2016·BMJ Open Diabetes Research & Care·Xiaomin SongJingyan Tian
Sep 30, 2016·Circulation·Xueli YangDongfeng Gu
Jun 1, 2017·JAMA Cardiology·Joshua D BundyJiang He
Aug 11, 2017·Diabetes Care·Adam P BressUNKNOWN SPRINT Research Group
Aug 24, 2017·Diabetes Care·Ian H de BoerGeorge Bakris
Aug 31, 2017·Scientific Reports·Jingyan TianGuang Ning
Nov 15, 2017·Hypertension·Paul K WheltonJackson T Wright
Dec 8, 2017·Diabetes Care·Tom F BrouwerReinoud E Knops
Dec 10, 2017·Diabetes Care·UNKNOWN American Diabetes Association
Dec 22, 2017·Diabetes Care·William T CefaluMatthew C Riddle
Feb 13, 2018·Circulation·Ji-Guang Wang, Lisheng Liu
Mar 16, 2018·JAMA : the Journal of the American Medical Association·Ian H de BoerChristopher P Cannon
Apr 25, 2018·Hypertension·Daniel T LacklandUNKNOWN World Hypertension League
Apr 25, 2018·Hypertension·George StergiouGianfranco Parati
Apr 25, 2018·Hypertension·Kazuomi Kario, Ji-Guang Wang
Citations
Apr 2, 2020·Diabetes Care·Chang-Sheng ShengGuang Ning
Mar 21, 2020·Diabetes Care·Jingyan TianJohn Chalmers
Aug 6, 2020·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Chao-Lei ChenYing-Qing Feng
Jan 21, 2020·Clinical and Experimental Hypertension : CHE·Xing Zhen LiuYi Xin Ji
Jan 15, 2021·BMJ Open·Nanfang LiQing Zhu
Mar 9, 2021·Blood Pressure·Mengyue LinNanfang Li
Apr 5, 2021·The Journal of Clinical Hypertension·Yanlong RenChangsheng Ma
May 27, 2021·Diabetes Care·Mayuko Harada YamadaHirohito Sone